Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Genitourinary 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cytarabine 83Methotrexate 59Cyclophosphamide 58Vincristine 47Daunorubicin 46Prednisone 33Mercaptopurine 33Asparaginase 33Dexamethasone 31Doxorubicin 29Gene Expression Profiling 27Etoposide 27pegaspargase 25Radiotherapy 25Filgrastim 25Thioguanine 24Leucovorin 24Flow Cytometry 23merphos 22Hydrocortisone 20Calcium Dobesilate 20Specimen Handling 18Microarray Analysis 16Idarubicin 16Granulocyte Colony-Stimulating Factor 15Peripheral Blood Stem Cell Transplantation 14Busulfan 14Polymerase Chain Reaction 13Mitoxantrone 13Gemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Hyaluronoglucosaminidase × Other hematologic neoplasm × Clear all
NCT05289687 2026-05-05

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Eastern Cooperative Oncology Group

Phase 2 Recruiting
20 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡